Dutch vaccine developer Mucosis has announced that John Lambert has been elected as the new chairman of its supervisory board. Mucosis is developing vaccines based on particles created from inactivated Lactococcus lactis bacteria, including its lead candidate, an intranasal influenza vaccine called FluGEM. Read the company’s press release
Mucosis elects new chairman
published on
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
June 9-June 10: Nasal Drug Delivery Symposium: Current Status and Future Opportunities, Stockholm, Sweden
June 10: SMI.London 2026, London, UK
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
